{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:58:55Z","timestamp":1793890735360,"version":"4.8.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a primary first-line treatment for type 2 diabetes. This has raised concerns about their impact on cancer risk, spurring extensive research. This review systematically examines the varied effects of GLP-1RAs on the risk of different types of tumors, including overall cancer risk and specific cancers such as thyroid, pancreatic, reproductive system, liver, and colorectal cancers. The potential biological mechanisms underlying their influence on cancer risk are complex, involving metabolic regulation, direct antitumor effects, immune modulation, and epigenetic changes. A systematic comparison with other antidiabetic agents reveals notable differences in their influence on cancer risk across drug classes. Additionally, critical factors that shape the relationship between GLP-1RAs and cancer risk are thoroughly analyzed, including patient demographics, comorbidities, treatment regimens, and lifestyle factors, offering essential insights for developing individualized treatment protocols. Despite significant research progress, critical gaps remain. Future research should prioritize elucidating the molecular mechanisms behind the antitumor effects, refining individualized treatment strategies, investigating early tumor prevention applications, assessing potential benefits for non-diabetic populations, advancing the development of novel therapies, establishing robust safety monitoring frameworks, and building precision medicine decision-making platforms. These efforts aim to establish novel roles for GLP-1RAs in cancer prevention. and treatment, thereby advancing the progress of precision medicine.<\/jats:p>","DOI":"10.1186\/s40364-025-00765-3","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T23:39:04Z","timestamp":1743032344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence"],"prefix":"10.1186","volume":"13","author":[{"given":"Anqi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoqu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank Z. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"8","key":"765_CR1","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3390\/ijms25084346","volume":"25","author":"CVI Feier","year":"2024","unstructured":"Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: a systematic literature review. Int J Mol Sci. 2024;25(8):4346.","journal-title":"Int J Mol Sci"},{"key":"765_CR2","first-page":"403","volume":"34","author":"AE Espinosa De Ycaza","year":"2024","unstructured":"Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-like peptide-1 receptor agonists and thyroid cancer: a narrative review. Thyroid. 2024;34:403\u201318.","journal-title":"Thyroid"},{"key":"765_CR3","doi-asserted-by":"publisher","first-page":"102834","DOI":"10.1016\/j.dsx.2023.102834","volume":"17","author":"L Nagendra","year":"2023","unstructured":"Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023;17:102834.","journal-title":"Diabetes Metab Syndr"},{"key":"765_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc22-1148","volume":"46","author":"J Bezin","year":"2023","unstructured":"Bezin J, Gouverneur A, P\u00e9nichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384\u201390.","journal-title":"Diabetes Care"},{"key":"765_CR5","doi-asserted-by":"publisher","first-page":"e078225","DOI":"10.1136\/bmj-2023-078225","volume":"385","author":"B Pasternak","year":"2024","unstructured":"Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbj\u00f6rnsdottir S, Jonasson C, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: scandinavian cohort study. BMJ. 2024;385:e078225.","journal-title":"BMJ"},{"key":"765_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41598-023-27509-3","volume":"13","author":"A Juji\u0107","year":"2023","unstructured":"Juji\u0107 A, Godina C, Belting M, Melander O, Juul Holst J, Ahlqvist E, et al. Endogenous incretin levels and risk of first incident cancer: a prospective cohort study. Sci Rep. 2023;13:382.","journal-title":"Sci Rep"},{"key":"765_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","volume":"68","author":"C Cao","year":"2020","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020;68:518\u201325.","journal-title":"Endocrine"},{"key":"765_CR8","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.3748\/wjg.v28.i25.2881","volume":"28","author":"V Suryadevara","year":"2022","unstructured":"Suryadevara V, Roy A, Sahoo J, Kamalanathan S, Naik D, Mohan P, et al. Incretin based therapy and pancreatic cancer: realising the reality. World J Gastroenterol. 2022;28:2881\u20139.","journal-title":"World J Gastroenterol"},{"key":"765_CR9","doi-asserted-by":"publisher","first-page":"e230257","DOI":"10.1530\/EC-23-0257","volume":"12","author":"G Lisco","year":"2023","unstructured":"Lisco G, De Tullio A, Disoteo O, Piazzolla G, Guastamacchia E, Sabb\u00e0 C, et al. Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned? Endocr Connect. 2023;12:e230257.","journal-title":"Endocr Connect"},{"key":"765_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-022-01344-7","volume":"25","author":"CS S\u00f8ndergaard","year":"2023","unstructured":"S\u00f8ndergaard CS, Esquivel PN, Dalamaga M, Magkos F. Use of antihyperglycemic drugs and risk of cancer in patients with diabetes. Curr Oncol Rep. 2023;25:29\u201340.","journal-title":"Curr Oncol Rep"},{"key":"765_CR11","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/nu15173737","volume":"15","author":"CM Cuttica","year":"2023","unstructured":"Cuttica CM, Briata IM, DeCensi A. Novel treatments for obesity: implications for cancer prevention and treatment. Nutrients. 2023;15:3737.","journal-title":"Nutrients"},{"key":"765_CR12","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s00125-010-1796-7","volume":"53","author":"XH Zhou","year":"2010","unstructured":"Zhou XH, Qiao Q, Zethelius B, Py\u00f6r\u00e4l\u00e4 K, S\u00f6derberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867\u201376.","journal-title":"Diabetologia"},{"key":"765_CR13","doi-asserted-by":"publisher","unstructured":"Aslam B, Bin Zafar MD, Changez MIK, Abdullah M, Safwan M, Qamar B, et al. Exploring the potential impact of GLP-1 receptor agonists in cancer therapy. Minerva Endocrinol. 2023. https:\/\/doi.org\/10.23736\/S2724-6507.23.04101-5.","DOI":"10.23736\/S2724-6507.23.04101-5"},{"key":"765_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1677\/ERC-09-0170","volume":"17","author":"M Luconi","year":"2010","unstructured":"Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, et al. Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer. 2010;17:169\u201377.","journal-title":"Endocr Relat Cancer"},{"key":"765_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1021\/acs.jproteome.3c00498","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Chen S, Zhen R. Effect of semaglutide on high-fat-diet-induced liver cancer in obese mice. J Proteome Res. 2024;23:704\u201317.","journal-title":"J Proteome Res"},{"key":"765_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","volume":"23","author":"S Peng","year":"2024","unstructured":"Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024;23:58.","journal-title":"Mol Cancer"},{"key":"765_CR17","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63:3891\u2013905.","journal-title":"Diabetes"},{"key":"765_CR18","doi-asserted-by":"publisher","first-page":"120370","DOI":"10.1016\/j.lfs.2022.120370","volume":"294","author":"Z-Z Liu","year":"2022","unstructured":"Liu Z-Z, Duan X-X, Yuan M-C, Yu J, Hu X, Han X, et al. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4\/ROS\/VEGF pathway. Life Sci. 2022;294:120370.","journal-title":"Life Sci"},{"key":"765_CR19","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/cancers16132377","volume":"16","author":"T Tabernacki","year":"2024","unstructured":"Tabernacki T, Wang L, Kaelber DC, Xu R, Berger NA. Non-insulin antidiabetic agents and lung cancer risk in drug-naive patients with type 2 diabetes mellitus: a nationwide retrospective cohort study. Cancers. 2024;16:2377.","journal-title":"Cancers"},{"key":"765_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","volume":"47","author":"J Wang","year":"2022","unstructured":"Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47:18\u201325.","journal-title":"Endocr Res"},{"key":"765_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jcpt.13259","volume":"46","author":"G Mali","year":"2021","unstructured":"Mali G, Ahuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the european pharmacovigilance database. J Clin Pharm Ther. 2021;46:99\u2013105.","journal-title":"J Clin Pharm Ther"},{"key":"765_CR22","doi-asserted-by":"publisher","unstructured":"Makunts T, Joulfayan H, Abagyan R. Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA adverse event reporting system. MedRxiv. 2023;2023.11.19.23298750. https:\/\/doi.org\/10.1101\/2023.11.19.23298750.","DOI":"10.1101\/2023.11.19.23298750"},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1210\/en.2010-0115","volume":"151","author":"PL Brubaker","year":"2010","unstructured":"Brubaker PL. Minireview: update on incretin biology: focus on glucagon-like peptide-1. Endocrinology. 2010;151:1984\u20139.","journal-title":"Endocrinology"},{"key":"765_CR24","doi-asserted-by":"publisher","first-page":"146597","DOI":"10.1016\/j.gene.2022.146597","volume":"834","author":"RS Abdul-Maksoud","year":"2022","unstructured":"Abdul-Maksoud RS, Elsayed WSH, Rashad NM, Elsayed RS, Elshorbagy S, Hamed MG. GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the egyptian population. Gene. 2022;834:146597.","journal-title":"Gene"},{"key":"765_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","volume":"45","author":"M Cao","year":"2023","unstructured":"Cao M, Pan C, Tian Y, Wang L, Zhao Z, Zhu B. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA adverse event reporting system and literature visualization analysis. Int J Clin Pharm. 2023;45:689\u201397.","journal-title":"Int J Clin Pharm"},{"key":"765_CR26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/cancers16091625","volume":"16","author":"M Ayoub","year":"2024","unstructured":"Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E. The use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus does not increase the risk of pancreatic cancer: a U.S.-based cohort study. Cancers. 2024;16:1625.","journal-title":"Cancers."},{"key":"765_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/pds.5550","volume":"32","author":"K Hidayat","year":"2023","unstructured":"Hidayat K, Zhou Y-Y, Du H-Z, Qin L-Q, Shi B-M, Li Z-N. A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer. Pharmacoepidemiol Drug Saf. 2023;32:107\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"765_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","volume":"66","author":"C Cao","year":"2019","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66:157\u201365.","journal-title":"Endocrine"},{"key":"765_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31083\/j.fbl2810259","volume":"28","author":"Z Pu","year":"2023","unstructured":"Pu Z, Yang Y, Qin S, Li X, Cui C, Chen W. The effect of liraglutide on lung cancer and its potential protective effect on high glucose-induced lung senescence and oxidative damage. Front Biosci. 2023;28:259.","journal-title":"Front Biosci"},{"key":"765_CR30","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1097\/JS9.0000000000001725","volume":"110","author":"G Zhang","year":"2024","unstructured":"Zhang G, Wang Z, Yu H, Liu X. A commentary on \u201cassociation of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials.\u201d Int J Surg. 2024;110:6034\u20135.","journal-title":"Int J Surg"},{"key":"765_CR31","doi-asserted-by":"publisher","first-page":"1392375","DOI":"10.3389\/fonc.2024.1392375","volume":"14","author":"F Crowley","year":"2024","unstructured":"Crowley F, Brown S, Gallagher EJ, Dayan JH. GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report. Front Oncol. 2024;14:1392375.","journal-title":"Front Oncol"},{"key":"765_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1507\/endocrj.EJ19-0428","volume":"67","author":"S Komatsu","year":"2020","unstructured":"Komatsu S, Nomiyama T, Numata T, Kawanami T, Hamaguchi Y, Iwaya C, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J. 2020;67:99\u2013106.","journal-title":"Endocr J"},{"key":"765_CR33","doi-asserted-by":"publisher","first-page":"109641","DOI":"10.1016\/j.cbi.2021.109641","volume":"349","author":"A Chequin","year":"2021","unstructured":"Chequin A, Costa LE, de Campos FF, Moncada ADB, de Lima LTF, Sledz LR, et al. Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021;349:109641.","journal-title":"Chem Biol Interact"},{"key":"765_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/EDE.0000000000001196","volume":"31","author":"C Santella","year":"2020","unstructured":"Santella C, Yin H, Hicks BM, Yu OHY, Bouganim N, Azoulay L. Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes. Epidemiol. 2020;31:559\u201366.","journal-title":"Epidemiol"},{"key":"765_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1248\/yakushi.23-00168-3","volume":"144","author":"M Ono","year":"2024","unstructured":"Ono M. radiotheranostics based on chemical control of radioactivity pharmacokinetics. Yakugaku Zasshi. 2024;144:291\u20137.","journal-title":"Yakugaku Zasshi"},{"key":"765_CR36","first-page":"e230015","volume":"4","author":"MS Stein","year":"2024","unstructured":"Stein MS, Kalff V, Williams SG, Murphy DG, Colman PG, Hofman MS. The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. Endocr Oncol. 2024;4:e230015.","journal-title":"Endocr Oncol"},{"key":"765_CR37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"765_CR38","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1097\/JS9.0000000000001514","volume":"110","author":"Y Sun","year":"2024","unstructured":"Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials. Int J Surg. 2024;110:4688\u201394.","journal-title":"Int J Surg"},{"key":"765_CR39","doi-asserted-by":"publisher","first-page":"9455","DOI":"10.2147\/OTT.S259853","volume":"13","author":"M Yan","year":"2020","unstructured":"Yan M, Shen M, Xu L, Huang J, He G, An M, et al. Inactivation of pancreatic stellate cells by exendin-4 inhibits the migration and invasion of pancreatic cancer cells. OncoTargets Ther. 2020;13:9455\u201363.","journal-title":"OncoTargets Ther"},{"key":"765_CR40","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3892\/or.2015.4476","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Xu F, Liang H, Cai M, Wen X, Li X, et al. Exenatide inhibits the growth of endometrial cancer ishikawa xenografts in nude mice. Oncol Rep. 2016;35:1340\u20138.","journal-title":"Oncol Rep"},{"key":"765_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/life14070835","volume":"14","author":"G Leipold","year":"2024","unstructured":"Leipold G, T\u00f3th R, H\u00e1rsfalvi P, L\u0151czi L, T\u00f6r\u00f6k M, Keszthelyi A, et al. Comprehensive evaluation of a levonorgestrel intrauterine device (LNG-IUD), metformin, and liraglutide for fertility preservation in endometrial cancer: protocol for a randomized clinical trial. Life. 2024;14:835.","journal-title":"Life"},{"key":"765_CR42","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","volume":"167","author":"L Wang","year":"2024","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024;167:689\u2013703.","journal-title":"Gastroenterology"},{"key":"765_CR43","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/hep.32439","volume":"76","author":"MC Plaz Torres","year":"2022","unstructured":"Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatol. 2022;76:1880\u201397.","journal-title":"Hepatol"},{"key":"765_CR44","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","volume":"21","author":"M Kojima","year":"2020","unstructured":"Kojima M, Takahashi H, Kuwashiro T, Tanaka K, Mori H, Ozaki I, et al. Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21:5722.","journal-title":"Int J Mol Sci"},{"key":"765_CR45","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol. 2024;10:256\u20138.","journal-title":"JAMA Oncol"},{"key":"765_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","volume":"21","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 2015;21:379\u201391.","journal-title":"Cell Metab"},{"key":"765_CR47","doi-asserted-by":"publisher","first-page":"12409","DOI":"10.3390\/ijms222212409","volume":"22","author":"J Vekic","year":"2021","unstructured":"Vekic J, Zeljkovic A, Stefanovic A, Giglio RV, Ciaccio M, Rizzo M. Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents. Int J Mol Sci. 2021;22:12409.","journal-title":"Int J Mol Sci"},{"key":"765_CR48","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dme.14287","volume":"37","author":"J Rouette","year":"2020","unstructured":"Rouette J, Yin H, Yu OHY, Bouganim N, Platt RW, Azoulay L. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. Diabet Med. 2020;37:868\u201375.","journal-title":"Diabet Med"},{"key":"765_CR49","doi-asserted-by":"publisher","first-page":"e15248","DOI":"10.1111\/dme.15248","volume":"41","author":"R Pradhan","year":"2024","unstructured":"Pradhan R, Yu OHY, Platt RW, Azoulay L. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: population-based cohort study. Diabet Med. 2024;41:e15248.","journal-title":"Diabet Med"},{"key":"765_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO.2002.20.1.42","volume":"20","author":"PJ Goodwin","year":"2002","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20:42\u201351.","journal-title":"J Clin Oncol"},{"key":"765_CR51","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1210\/clinem\/dgaa891","volume":"106","author":"GF Piccoli","year":"2021","unstructured":"Piccoli GF, Mesquita LA, Stein C, Aziz M, Zoldan M, Degobi NAH, et al. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:912\u201321.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9945","key":"765_CR52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","volume":"384","author":"K Bhaskaran","year":"2014","unstructured":"Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5\u00b7 24 million UK adults. Lancet. 2014;384(9945):755\u201365.","journal-title":"Lancet"},{"key":"765_CR53","doi-asserted-by":"publisher","unstructured":"Shi X, Jiang A, Qiu Z, Lin A, Liu Z, Zhu L, et al. Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications. Front Med. 2024;18(6):945-68. https:\/\/doi.org\/10.1007\/s11684-024-1094-2.","DOI":"10.1007\/s11684-024-1094-2"},{"key":"765_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/cancers15020485","volume":"15","author":"S Pati","year":"2023","unstructured":"Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers. 2023;15:485.","journal-title":"Cancers"},{"key":"765_CR55","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/en.2017-00461","volume":"158","author":"C Iwaya","year":"2017","unstructured":"Iwaya C, Nomiyama T, Komatsu S, Kawanami T, Tsutsumi Y, Hamaguchi Y, et al. Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-\u03baB activation. Endocrinology. 2017;158:4218\u201332.","journal-title":"Endocrinology"},{"key":"765_CR56","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2174\/1874467215666221005123919","volume":"16","author":"N Faheem","year":"2023","unstructured":"Faheem N, Sivasubrmanian S. Fathoming the role of mTOR in diabetes mellitus and its complications. Curr Mol Pharmacol. 2023;16:520\u20139.","journal-title":"Curr Mol Pharmacol"},{"key":"765_CR57","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/cancers16081538","volume":"16","author":"A Alhajahjeh","year":"2024","unstructured":"Alhajahjeh A, Al-Faouri R, Bahmad HF, Bader T, Dobbs RW, Abdulelah AA, et al. From diabetes to oncology: glucagon-like peptide-1 (GLP-1) receptor agonist\u2019s dual role in prostate cancer. Cancers. 2024;16:1538.","journal-title":"Cancers"},{"key":"765_CR58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/CM9.0000000000001363","volume":"134","author":"X-X Zhu","year":"2021","unstructured":"Zhu X-X, Feng Z-H, Liu L-Z, Zhang Y. Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5\u2019-monophosphate (AMP)-activated protein kinase signaling pathway. Chin Med J (Engl). 2021;134:576\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"765_CR59","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14715\/cmb\/2023.69.14.37","volume":"69","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang L, Wang B, Zhang X, Gu L, Guo K, et al. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells. Cell Mol Biol. 2023;69:221\u20135.","journal-title":"Cell Mol Biol"},{"key":"765_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Tr. 2012;132:449\u201361.","journal-title":"Breast Cancer Res Tr"},{"key":"765_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Kong Q, Wang J, Jiang Y, Hua H. Complex roles of cAMP-PKA-CREB signaling in cancer. Exp Hematol Oncol. 2020;9:32.","journal-title":"Exp Hematol Oncol"},{"key":"765_CR62","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"JA Koehler","year":"2011","unstructured":"Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152:3362\u201372.","journal-title":"Endocrinology"},{"key":"765_CR63","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/dom.12291","volume":"16","author":"H Zhao","year":"2014","unstructured":"Zhao H, Wang L, Wei R, Xiu D, Tao M, Ke J, et al. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/akt pathway. Diabetes Obes Metab. 2014;16:850\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"765_CR64","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2017.05.015","volume":"809","author":"GC Krause","year":"2017","unstructured":"Krause GC, Lima KG, Dias HB, da Silva EFG, Haute GV, Basso BS, et al. Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells. Eur J Pharmacol. 2017;809:32\u201341.","journal-title":"Eur J Pharmacol"},{"key":"765_CR65","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/pros.23687","volume":"78","author":"W He","year":"2018","unstructured":"He W, Li J. Exendin-4 enhances radiation response of prostate cancer. Prostate. 2018;78:1125\u201333.","journal-title":"Prostate"},{"key":"765_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1530\/JME-19-0186","volume":"64","author":"H-J Zhao","year":"2020","unstructured":"Zhao H-J, Jiang X, Hu L-J, Yang L, Deng L-D, Wang Y-P, et al. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. J Mol Endocrinol. 2020;64:103\u201313.","journal-title":"J Mol Endocrinol"},{"key":"765_CR67","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/jdi.13247","volume":"11","author":"T Shigeoka","year":"2020","unstructured":"Shigeoka T, Nomiyama T, Kawanami T, Hamaguchi Y, Horikawa T, Tanaka T, et al. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. J Diabetes Investig. 2020;11:1137\u201349.","journal-title":"J Diabetes Investig"},{"key":"765_CR68","doi-asserted-by":"publisher","first-page":"186","DOI":"10.14712\/fb2020066050186","volume":"66","author":"RM Badi","year":"2020","unstructured":"Badi RM, Khaleel EF, El-Bidawy MH, Satti HH, Mostafa DG. Exendin-4 induces cytotoxic autophagy in two ovarian cancer cell lines through inhibition of Mtorc1 mediated by activation of AMPK and suppression of akt. Folia Biol (Praha). 2020;66:186\u2013203.","journal-title":"Folia Biol (Praha)"},{"key":"765_CR69","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/pros.23951","volume":"80","author":"H Wenjing","year":"2020","unstructured":"Wenjing H, Shao Y, Yu Y, Huang W, Feng G, Li J. Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting akt activation. Prostate. 2020;80:367\u201375.","journal-title":"Prostate"},{"key":"765_CR70","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","volume":"36","author":"M Zhou","year":"2017","unstructured":"Zhou M, Mok MT, Sun H, Chan AW, Huang Y, Cheng AS, et al. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene. 2017;36:4135\u201349.","journal-title":"Oncogene"},{"key":"765_CR71","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12885-023-11077-w","volume":"23","author":"B Ma","year":"2023","unstructured":"Ma B, Wang X, Ren H, Li Y, Zhang H, Yang M, et al. High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist. BMC Cancer. 2023;23:594.","journal-title":"BMC Cancer"},{"key":"765_CR72","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.mce.2016.07.032","volume":"436","author":"W He","year":"2016","unstructured":"He W, Yu S, Wang L, He M, Cao X, Li Y, et al. Exendin-4 inhibits growth and augments apoptosis of ovarian cancer cells. Mol Cell Endocrinol. 2016;436:240\u20139.","journal-title":"Mol Cell Endocrinol"},{"key":"765_CR73","doi-asserted-by":"publisher","first-page":"e18761429273223","DOI":"10.2174\/0118761429273223231124072223","volume":"17","author":"D Karati","year":"2024","unstructured":"Karati D, Kumar D. Molecular insight into the apoptotic mechanism of cancer cells: an explicative review. Curr Mol Pharmacol. 2024;17:e18761429273223.","journal-title":"Curr Mol Pharmacol"},{"key":"765_CR74","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s13277-015-4104-9","volume":"37","author":"G Fidan-Yaylal\u0131","year":"2016","unstructured":"Fidan-Yaylal\u0131 G, Dodurga Y, Se\u00e7me M, Elmas L. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016;37:2647\u201353.","journal-title":"Tumour Biol"},{"key":"765_CR75","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","volume":"83","author":"K Natarajan","year":"2012","unstructured":"Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83:1084\u2013103.","journal-title":"Biochem Pharmacol"},{"key":"765_CR76","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jmb.2018.01.017","volume":"430","author":"AH Phillips","year":"2018","unstructured":"Phillips AH, Ou L, Gay A, Besson A, Kriwacki RW. Mapping interactions between p27 and RhoA that stimulate cell migration. J Mol Biol. 2018;430:751\u20138.","journal-title":"J Mol Biol"},{"key":"765_CR77","doi-asserted-by":"publisher","first-page":"901559","DOI":"10.3389\/fphar.2022.901559","volume":"13","author":"G Tong","year":"2022","unstructured":"Tong G, Peng T, Chen Y, Sha L, Dai H, Xiang Y, et al. Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway. Front Pharmacol. 2022;13:901559.","journal-title":"Front Pharmacol"},{"key":"765_CR78","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1530\/EC-17-0294","volume":"6","author":"A Kosowska","year":"2017","unstructured":"Kosowska A, Gallego-Colon E, Garczorz W, K\u0142ych-Ratuszny A, Aghdam MRF, Woz Niak M, et al. Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect. 2017;6:856\u201365.","journal-title":"Endocr Connect"},{"key":"765_CR79","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.atherosclerosis.2010.07.061","volume":"213","author":"K Tsoyi","year":"2010","unstructured":"Tsoyi K, Jang HJ, Nizamutdinova IT, Park K, Kim YM, Kim HJ, et al. PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K\/akt\/GSK-3\u03b2\/GATA-6 signaling pathways in TNF-\u03b1-activated human endothelial cells. Atherosclerosis. 2010;213:115\u201321.","journal-title":"Atherosclerosis"},{"key":"765_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/457036b","volume":"457","author":"A Mantovani","year":"2009","unstructured":"Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457:36\u20137.","journal-title":"Nature"},{"key":"765_CR81","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3109\/07357900902769749","volume":"27","author":"N Makrilia","year":"2009","unstructured":"Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27:1023\u201337.","journal-title":"Cancer Invest"},{"key":"765_CR82","first-page":"e060923220758","volume":"17","author":"SM Manohar","year":"2024","unstructured":"Manohar SM. At the crossroads of TNF \u03b1 signaling and cancer. Curr Mol Pharmacol. 2024;17:e060923220758.","journal-title":"Curr Mol Pharmacol"},{"key":"765_CR83","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00404-012-2456-6","volume":"286","author":"X Hu","year":"2012","unstructured":"Hu X, Li D, Zhang W, Zhou J, Tang B, Li L. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion. Arch Gynecol Obstet. 2012;286:1537\u201343.","journal-title":"Arch Gynecol Obstet"},{"key":"765_CR84","first-page":"92","volume":"371","author":"S-C Liu","year":"2006","unstructured":"Liu S-C, Yang S-F, Yeh K-T, Yeh C-M, Chiou H-L, Lee C-Y, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin. 2006;371:92\u20136.","journal-title":"Clin"},{"key":"765_CR85","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1158\/1535-7163.MCT-08-0251","volume":"7","author":"K Almholt","year":"2008","unstructured":"Almholt K, Juncker-Jensen A, Laerum OD, Dan\u00f8 K, Johnsen M, Lund LR, et al. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther. 2008;7:2758\u201367.","journal-title":"Mol Cancer Ther"},{"key":"765_CR86","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nrc3341","volume":"12","author":"BE Henderson","year":"2012","unstructured":"Henderson BE, Lee NH, Seewaldt V, Shen H. The influence of race and ethnicity on the biology of cancer. Nat Rev Cancer. 2012;12:648\u201353.","journal-title":"Nat Rev Cancer"},{"key":"765_CR87","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.biopha.2018.07.092","volume":"106","author":"Z-J Nie","year":"2018","unstructured":"Nie Z-J, Zhang Y-G, Chang Y-H, Li Q-Y, Zhang Y-L. Exendin-4 inhibits glioma cell migration, invasion and epithelial-to-mesenchymal transition through GLP-1R\/sirt3 pathway. Biomed Pharmacother Biomedecine Pharmacother. 2018;106:1364\u20139.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"765_CR88","doi-asserted-by":"publisher","first-page":"1387243","DOI":"10.3389\/fphar.2024.1387243","volume":"15","author":"C Zhu","year":"2024","unstructured":"Zhu C, Lai Y, Liu C, Teng L, Zhu Y, Lin X, et al. Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer. Front Pharmacol. 2024;15:1387243.","journal-title":"Front Pharmacol"},{"key":"765_CR89","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54:2701\u201311.","journal-title":"Immunity"},{"key":"765_CR90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1874467215666220324114624","volume":"16","author":"E Abdollahi","year":"2023","unstructured":"Abdollahi E, Johnston TP, Ghaneifar Z, Vahedi P, Goleij P, Azhdari S, et al. Immunomodulatory therapeutic effects of curcumin on M1\/M2 macrophage polarization in inflammatory diseases. Curr Mol Pharmacol. 2023;16:2\u201314.","journal-title":"Curr Mol Pharmacol"},{"key":"765_CR91","doi-asserted-by":"publisher","first-page":"100872","DOI":"10.1016\/j.tranon.2020.100872","volume":"14","author":"X Lu","year":"2021","unstructured":"Lu X, Xu C, Dong J, Zuo S, Zhang H, Jiang C, et al. Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma. Transl Oncol. 2021;14:100872.","journal-title":"Transl Oncol"},{"key":"765_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbrc.2022.06.052","volume":"619","author":"D Chen","year":"2022","unstructured":"Chen D, Li Q, Liang H, Huang L, Zhou H, Zheng X, et al. Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps. Biochem Biophys Res Commun. 2022;619:97\u2013103.","journal-title":"Biochem Biophys Res Commun"},{"key":"765_CR93","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/2211-5463.13499","volume":"14","author":"D Chen","year":"2024","unstructured":"Chen D, Liang H, Huang L, Zhou H, Wang Z. Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps. FEBS Open Bio. 2024;14:1365\u201377.","journal-title":"FEBS Open Bio"},{"key":"765_CR94","doi-asserted-by":"publisher","first-page":"bqaa201","DOI":"10.1210\/endocr\/bqaa201","volume":"161","author":"T Sato","year":"2020","unstructured":"Sato T, Shimizu T, Fujita H, Imai Y, Drucker DJ, Seino Y, et al. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in Male mice. Endocrinology. 2020;161:bqaa201.","journal-title":"Endocrinology."},{"key":"765_CR95","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4254\/wjh.v12.i8.493","volume":"12","author":"A Sofogianni","year":"2020","unstructured":"Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: an update. World J Hepatol. 2020;12:493\u2013505.","journal-title":"World J Hepatol"},{"key":"765_CR96","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2174\/1568009621666210901101851","volume":"21","author":"P Jaiswal","year":"2021","unstructured":"Jaiswal P, Tripathi V, Nayak A, Kataria S, Lukashevich V, Das AK, et al. A molecular link between diabetes and breast cancer: therapeutic potential of repurposing incretin-based therapies for breast cancer. Curr Cancer Drug Targets. 2021;21:829\u201348.","journal-title":"Curr Cancer Drug Targets"},{"key":"765_CR97","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbrc.2020.06.054","volume":"529","author":"B Zhou","year":"2020","unstructured":"Zhou B, Dong C, Zhao B, Su X, Luo Y, Xie L, et al. (EX-4)2-fc, an effective long-acting GLP-1 receptor agonist, reduces obesity-related inflammation by inhibiting leptin expression. Biochem Biophys Res Commun. 2020;529:562\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"765_CR98","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2217\/epi-2023-0332","volume":"15","author":"JM Tatsch","year":"2023","unstructured":"Tatsch JM, Furman DP, Nobre RM, Wurzer KM, da Silva LC, Picheth GF, et al. Dulaglutide as a demethylating agent to improve the outcome of breast cancer. Epigenomics. 2023;15:1309\u201322.","journal-title":"Epigenomics"},{"key":"765_CR99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.mehy.2013.11.034","volume":"82","author":"Y Sun","year":"2014","unstructured":"Sun Y, Fan L, Meng J, Zhang F, Zhang D, Mei Q. Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer? Med Hypotheses. 2014;82:255\u20136.","journal-title":"Med Hypotheses"},{"key":"765_CR100","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","volume":"17","author":"P Polakis","year":"2007","unstructured":"Polakis P. The many ways of wnt in cancer. Curr Opin Genet Dev. 2007;17:45\u201351.","journal-title":"Curr Opin Genet Dev"},{"key":"765_CR101","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-021-06288-3","volume":"189","author":"N Hashimoto Takigami","year":"2021","unstructured":"Hashimoto Takigami N, Kuniyoshi S, Miki Y, Tamaki K, Kamada Y, Uehara K, et al. Breast cancer, diabetes mellitus and glucagon-like peptide-1 receptor toward exploring their possible associations. Breast Cancer Res Treat. 2021;189:39\u201348.","journal-title":"Breast Cancer Res Treat"},{"key":"765_CR102","doi-asserted-by":"publisher","first-page":"106094","DOI":"10.1016\/j.phrs.2022.106094","volume":"177","author":"H Cui","year":"2022","unstructured":"Cui H, Wang Y, Yang S, He G, Jiang Z, Gang X, et al. Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Pharmacol Res. 2022;177:106094.","journal-title":"Pharmacol Res"},{"key":"765_CR103","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11154-023-09849-7","volume":"25","author":"G Brenta","year":"2024","unstructured":"Brenta G, Di Fermo F. Thyroid cancer and insulin resistance. Rev Endocr Metab Disord. 2024;25:19\u201334.","journal-title":"Rev Endocr Metab Disord"},{"key":"765_CR104","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s13340-021-00560-z","volume":"13","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Iwaya C, Kawanami T, Hamaguchi Y, Horikawa T, Shigeoka T, et al. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetol Int. 2022;13:480\u201392.","journal-title":"Diabetol Int"},{"key":"765_CR105","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","volume":"9","author":"K He","year":"2019","unstructured":"He K, Hu H, Ye S, Wang H, Cui R, Yi L. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis. Sci Rep. 2019;9:2218.","journal-title":"Sci Rep"},{"key":"765_CR106","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/cancers13081827","volume":"13","author":"M Knura","year":"2021","unstructured":"Knura M, Garczorz W, Borek A, Drzyma\u0142a F, Rachwa\u0142 K, George K, et al. The influence of anti-diabetic drugs on prostate cancer. Cancers. 2021;13:1827.","journal-title":"Cancers"},{"key":"765_CR107","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/dme.14179","volume":"37","author":"R Dankner","year":"2020","unstructured":"Dankner R, Roth J. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabet Med J Br Diabet Assoc. 2020;37:194\u2013202.","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"765_CR108","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.prro.2024.04.006","volume":"14","author":"K Andrianu","year":"2024","unstructured":"Andrianu K, Works D, Christiansen A, Enke C, Chaiken L, Baine M. Exploring the impact of sodium-glucose cotransporter-2 inhibitors on genitourinary toxicities in prostate cancer patients undergoing radiation therapy: a case study and discussion. Pract Radiat Oncol. 2024;14:373\u20136.","journal-title":"Pract Radiat Oncol"},{"key":"765_CR109","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.13924","volume":"22","author":"M Abd El Aziz","year":"2020","unstructured":"Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22:699\u2013704.","journal-title":"Diabetes Obes Metab."},{"key":"765_CR110","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/EDE.0000000000001486","volume":"33","author":"S Lu","year":"2022","unstructured":"Lu S, Yin H, Yu OHY, Azoulay L. Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes. Epidemiol Camb Mass. 2022;33:563\u201371.","journal-title":"Epidemiol Camb Mass"},{"key":"765_CR111","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","volume":"10","author":"M Kawakubo","year":"2020","unstructured":"Kawakubo M, Tanaka M, Ochi K, Watanabe A, Saka-Tanaka M, Kanamori Y, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020;10:983.","journal-title":"Sci Rep"},{"key":"765_CR112","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1007\/s00125-021-05508-1","volume":"64","author":"P Ueda","year":"2021","unstructured":"Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson A-M, Franz\u00e9n S, et al. Use of incretin-based drugs and risk of cholangiocarcinoma: scandinavian cohort study. Diabetologia. 2021;64:2204\u201314.","journal-title":"Diabetologia"},{"key":"765_CR113","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/dom.15292","volume":"26","author":"S Bea","year":"2024","unstructured":"Bea S, Son H, Bae JH, Cho SW, Shin J-Y, Cho YM. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab. 2024;26:108\u201317.","journal-title":"Diabetes Obes Metab"},{"key":"765_CR114","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/biom14060687","volume":"14","author":"S Capuccio","year":"2024","unstructured":"Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G, et al. Implications of GLP-1 receptor agonist on thyroid function: a literature review of its effects on thyroid volume, risk of cancer, functionality and TSH levels. Biomolecules. 2024;14:687.","journal-title":"Biomolecules"},{"key":"765_CR115","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s00125-023-05972-x","volume":"66","author":"C Skriver","year":"2023","unstructured":"Skriver C, Friis S, Knudsen LB, Catarig A-M, Clark AJ, Dehlendorff C, et al. Potential preventive properties of GLP-1 receptor agonists against prostate cancer: a nationwide cohort study. Diabetologia. 2023;66:2007\u201316.","journal-title":"Diabetologia"},{"key":"765_CR116","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139:e56-528.","journal-title":"Circulation"},{"key":"765_CR117","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0140-6736(09)60937-5","volume":"375","author":"A Ramachandran","year":"2010","unstructured":"Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Lancet. 2010;375:408\u201318.","journal-title":"Lancet"},{"key":"765_CR118","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/157339906777950606","volume":"2","author":"S Dagogo-Jack","year":"2006","unstructured":"Dagogo-Jack S, Funnell MM, Davidson J. Barriers to achieving optimal glycemic control in a multi-ethnic society: a US focus. Curr Diabetes Rev. 2006;2:285\u201393.","journal-title":"Curr Diabetes Rev"},{"key":"765_CR119","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40615-016-0335-8","volume":"5","author":"JR Canedo","year":"2018","unstructured":"Canedo JR, Miller ST, Schlundt D, Fadden MK, Sanderson M. Racial\/ethnic disparities in diabetes quality of care: the role of healthcare access and socioeconomic status. J Racial Ethn Health Disparities. 2018;5:7\u201314.","journal-title":"J Racial Ethn Health Disparities"},{"key":"765_CR120","doi-asserted-by":"publisher","first-page":"103242","DOI":"10.1016\/j.ebiom.2021.103242","volume":"65","author":"D Mao","year":"2021","unstructured":"Mao D, Cao H, Shi M, Wang CC, Kwong J, Li JJX, et al. Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by exendin-4: a translational case-control study. EBioMedicine. 2021;65:103242.","journal-title":"EBioMedicine"},{"key":"765_CR121","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/biomedicines12020280","volume":"12","author":"B-E Mart\u00ednez-Herrera","year":"2024","unstructured":"Mart\u00ednez-Herrera B-E, Mu\u00f1oz-Garc\u00eda M-G, Jos\u00e9-Ochoa L-L, Quiroga-Morales L-A, Cerv\u00e1ntes-Gonz\u00e1lez L-M, Mireles-Ram\u00edrez M-A, et al. Role of incretins in muscle functionality, metabolism, and body composition in breast cancer: a metabolic approach to understanding this pathology. Biomedicines. 2024;12:280.","journal-title":"Biomedicines"},{"key":"765_CR122","doi-asserted-by":"publisher","first-page":"155932582199565","DOI":"10.1177\/1559325821995651","volume":"19","author":"AA Alanteet","year":"2021","unstructured":"Alanteet AA, Attia HA, Shaheen S, Alfayez M, Alshanawani B. Anti-proliferative activity of glucagon-like peptide-1 receptor agonist on obesity-associated breast cancer: the impact on modulating adipokines\u2019 expression in adipocytes and cancer cells. Dose-Response. 2021;19:1559325821995651.","journal-title":"Dose-Response"},{"key":"765_CR123","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41467-024-47359-5","volume":"15","author":"A Piening","year":"2024","unstructured":"Piening A, Ebert E, Gottlieb C, Khojandi N, Kuehm LM, Hoft SG, et al. Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk. Nat Commun. 2024;15:2835.","journal-title":"Nat Commun"},{"key":"765_CR124","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","volume":"13","author":"Z Yang","year":"2022","unstructured":"Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, et al. GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front Pharmacol. 2022;13:925377.","journal-title":"Front Pharmacol"},{"key":"765_CR125","doi-asserted-by":"crossref","unstructured":"Lee ATM, Ou S-HI, Lisberg A. Letter to editor. Re \u201cde leeuw SP, et al. Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer,\u201d semaglutide a potential treatment for serious weight gain from ALK tyrosine kinase inhibitors? J Thorac Oncol. 2023;18:e97\u20139.","DOI":"10.1016\/j.jtho.2023.04.014"},{"key":"765_CR126","doi-asserted-by":"publisher","first-page":"e18761429290933","DOI":"10.2174\/0118761429290933240408071812","volume":"17","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Hu Y, Yang C, Huang S, Wen J, Huang W, et al. Progress of angiogenesis signal pathway and antiangiogenic drugs in nasopharyngeal carcinoma. Curr Mol Pharmacol. 2024;17:e18761429290933.","journal-title":"Curr Mol Pharmacol"},{"key":"765_CR127","doi-asserted-by":"publisher","first-page":"107327482412411","DOI":"10.1177\/10732748241241158","volume":"31","author":"C Carbonell","year":"2024","unstructured":"Carbonell C, Mathew Stephen M, Ruan Y, Warkentin MT, Brenner DR. Next generation weight loss drugs for the prevention of cancer? Cancer Control. 2024;31:10732748241241158.","journal-title":"Cancer Control"},{"key":"765_CR128","first-page":"e41407","volume":"15","author":"M Al-Jafari","year":"2023","unstructured":"Al-Jafari M, Alrosan S, Alkhawaldeh IM, Zein Eddin S, Abu-Jeyyab M, Zuaiter SN. Dumping syndrome in children: a narrative review. Cureus. 2023;15:e41407.","journal-title":"Cureus"},{"key":"765_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpan.2024.11.001","volume":"21","author":"J Chen","year":"2024","unstructured":"Chen J, Lin A, Luo P. Advancing pharmaceutical research: a comprehensive review of cutting- edge tools and technologies. Curr Pharm Anal. 2024;21:1\u201319.","journal-title":"Curr Pharm Anal"},{"key":"765_CR130","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","volume":"21","author":"Z Wang","year":"2024","unstructured":"Wang Z, Zhao Y, Zhang L. Emerging trends and hot topics in the application of multi-omics in drug discovery: a bibliometric and visualized study. Curr Pharm Anal. 2024;21:20\u201332.","journal-title":"Curr Pharm Anal"},{"key":"765_CR131","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cpan.2024.12.002","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang S, Liu K, Hu X, Gu X. Advances in drug discovery based on network pharmacology and omics technology. Curr Pharm Anal. 2024;21:33\u201343.","journal-title":"Curr Pharm Anal"},{"key":"765_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-025-01435-2","volume":"8","author":"J Chen","year":"2025","unstructured":"Chen J, Lin A, Jiang A, Qi C, Liu Z, Cheng Q, et al. Computational frameworks transform antagonism to synergy in optimizing combination therapies. Npj Digit Med. 2025;8:1\u201322.","journal-title":"Npj Digit Med"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00765-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00765-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T06:20:41Z","timestamp":1743315641000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00765-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00765-3","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}